Amniotic IGF-I supplements improve gut growth but reduce circulating IGF-I in growth-restricted fetal sheep

被引:29
作者
Bloomfield, FH [1 ]
Bauer, MK [1 ]
Van Zijl, PL [1 ]
Gluckman, PD [1 ]
Harding, JE [1 ]
机构
[1] Univ Auckland, Liggins Inst, Auckland 1, New Zealand
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2002年 / 282卷 / 02期
关键词
intrauterine growth restriction; hormone; metabolism; fetal therapy; placenta;
D O I
10.1152/ajpendo.00200.2001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin-like growth factor I (IGF-I) is an important regulator of fetal growth, and circulating concentrations are reduced in intrauterine growth-restricted (IUGR) fetuses. We investigated whether IGF-I administered into amniotic fluid could ameliorate IUGR in fetal sheep. Fetuses were assigned to control (n = 9), IUGR+saline (n = 12), or IUGR+IGF-I groups (daily intra-amniotic IGF-I injections of 20 mug, n = 13). IUGR was induced by placental embolization from 114 to 120 days. Treatment was from 120 to 130 days of gestation. Embolization produced asymmetrically IUGR fetuses with decreased body weight and lighter, thinner-walled guts. Fetal plasma and amniotic IGF-I levels were reduced. During treatment, fetal plasma, but not amniotic, IGF-I levels recovered in the saline group but remained depressed in the IGF-I-treated group. IGF-I treatment restored gut weight and wall thickness to control levels and increased the number of crypt mitoses. Fetal weight was similar to that of controls, but spleen, liver, and thymic weights were reduced by 30-37%, and placentome growth was altered. Amniotic fluid IGF-I supplementation may provide the basis of future therapeutic approaches to IUGR, but the systemic effects require further investigation.
引用
收藏
页码:E259 / E269
页数:11
相关论文
共 66 条
  • [1] PROTEINS OF THE LIQUOR AMNII
    ABBAS, TM
    TOVEY, JE
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1960, 1 (FEB13): : 476 - 479
  • [2] Abu-Amero SN, 1998, MOL REPROD DEV, V49, P229, DOI 10.1002/(SICI)1098-2795(199803)49:3<229::AID-MRD2>3.0.CO
  • [3] 2-Q
  • [4] SMALL INTESTINAL DEVELOPMENT IN GROWTH-RETARDED FETAL SHEEP
    AVILA, CG
    HARDING, R
    REES, S
    ROBINSON, PM
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1989, 8 (04) : 507 - 515
  • [5] Barker D.J. P., 1994, MOTHERS BABIES DIS L
  • [6] In utero programming of chronic disease
    Barker, DJP
    [J]. CLINICAL SCIENCE, 1998, 95 (02) : 115 - 128
  • [7] MATERNAL HYPEROXYGENATION IN THE TREATMENT OF INTRAUTERINE GROWTH-RETARDATION
    BATTAGLIA, C
    ARTINI, PG
    DAMBROGIO, G
    GALLI, PA
    SEGRE, A
    GENAZZANI, AR
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1992, 167 (02) : 430 - 435
  • [8] Bloomfield F., 1998, FETAL MAT MED REV, V10, P91, DOI DOI 10.1017/S0965539597000235
  • [9] BLOOMFIELD FH, 2000, P ANN M END SOC 82 T, P232
  • [10] INFLUENCE OF NUTRITIONAL-STATUS AND OESTRADIOL-17-BETA ON PLASMA GROWTH-HORMONE, INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II AND THE RESPONSE TO EXOGENOUS GROWTH-HORMONE IN YOUNG STEERS
    BREIER, BH
    GLUCKMAN, PD
    BASS, JJ
    [J]. JOURNAL OF ENDOCRINOLOGY, 1988, 118 (02) : 243 - 250